Background Loss of cortical grey matter is a diagnostic marker of many neurodegenerative diseases, and is a key mediator of cognitive impairment. We postulated that cerebral amyloid angiopathy (CAA), characterised by cortical vascular amyloid deposits, is associated with cortical tissue loss independent of parenchymal Alzheimer's disease pathology. We tested this hypothesis in patients with hereditary cerebral haemorrhage with amyloidosis-Dutch type (HCHWA-D), a monogenetic disease with minimal or no concomitant Alzheimer's disease pathology, as well as in patients with sporadic CAA and healthy and Alzheimer's disease controls.
Introduction
Loss of cortical grey matter is a marker of many neurodegenerative diseases, such as Alzheimer's disease, and is a key mediator of associated cognitive impairment. 1, 2 Cortical atrophy has also been observed in cerebral small vessel disease, a disorder generally recognised as a cause of subcortical white matter injury. 3, 4 However, whether this observed atrophy in small vessel disease represents true loss of cortical grey matter, or simply results from the widening of cortical sulci due to loss of the underlying subcortical white matter, is unknown. 5 It is important to understand the specifi c contributors to cortical atrophy to test targeted therapeutic approaches.
Cerebral amyloid angiopathy (CAA) is characterised by the gradual deposition of amyloid β (Aβ) peptides in the media and adventitia of small leptomeningeal and cortical vessels. 6 CAA pathology has been identifi ed as a major cause of lobar intracerebral haemorrhage, microbleeds, and superfi cial siderosis. 7, 8 In recent years, fi ndings from multiple studies have shown that CAA also causes ischaemic subcortical tissue injury, an eff ect probably mediated by vascular dysfunction. [9] [10] [11] [12] As a result of such ischaemic damage, CAA pathology has emerged as an independent contributor to age-related cognitive decline, even in patients who have not had symptomatic intracerebral haemorrhage. 13, 14 Although CAA-a cortical vascular pathology-has been linked to many subcortical lesions, its association with cortical structural changes has not been studied. The most important impediment for such a study is the frequent coexistence of CAA and parenchymal Alzheimer's disease pathologies, making it diffi cult to tease out the independent eff ects of vascular amyloid on cerebral cortex. To overcome such confounding by parenchymal Alzheimer's disease, we analysed a unique cohort of patients with hereditary cerebral haemorrhage with amyloidosis-Dutch type (HCHWA-D), a condition characterised by severe CAA pathology with minimal or no neurofi brillary pathology. 15 To assess the generalisability of fi ndings from this select cohort, we further compared cortical thickness in patients with the more common sporadic CAA with age-matched healthy controls and individuals with Alzheimer's disease. We also examined the correlation between cortical thickness and markers of structural cerebral injury (lobar microbleeds and leukoaraiosis) to understand whether these widespread lesions might aff ect cortical loss or its measurement. Finally, we analysed the relationship between cortical thickness and a functional MRI (fMRI) marker of vascular reactivity to explore the possibility that CAA-related vascular dysfunction mediates cortical damage.
Methods

Study design and participants
This case-control study was done between March 15, 2006 , and Dec 1, 2014, at two tertiary referral centres: Leiden University in the Netherlands, and Massachusetts General Hospital in Boston, MA, USA. The cohort of patients with HCHWA-D and their age-matched healthy controls were enrolled at the Leiden University Medical Center, Leiden, Netherlands. 16 Controls were recruited from the spouses, extended family members, and friends of patients with
Research in context
Evidence before this study We searched PubMed for articles on cerebral amyloid angiopathy (CAA) and cortical atrophy published between Jan 1, 1990, and Nov 1, 2015, with diff erent combinations of the terms "cerebral amyloid angiopathy", "cortical atrophy", "cortical thickness", and "cortical damage", using no language restrictions. We did not fi nd any reports addressing the association between CAA and cortical atrophy. We then repeated PubMed searches within the same time interval using combinations of the term "cerebral amyloid angiopathy" and each one of the following terms: "leukoaraiosis", "white matter", "structural networks", and "subcortical injury". We found several articles establishing associations between CAA and subcortical tissue damage, but the association of CAA and cortical atrophy was unknown. A major obstacle in clarifying the association between CAA and cortical atrophy has been the relatively common presence of parenchymal Alzheimer's disease pathology in these patients, which is a well-established cause of cortical atrophy.
Added value of this study
This study shows that patients with hereditary cerebral haemorrhage with amyloidosis-Dutch type, a monogenetic disease with little or no concomitant parenchymal Alzheimer's disease pathology, have decreased cortical thickness when compared to age-matched healthy controls. These fi ndings were confi rmed by comparing a well-defi ned cohort of elderly patients with sporadic CAA to age-matched healthy controls.
Mediation analyses also showed that vascular dysfunction explained at least part of the eff ect of CAA pathology on cortical atrophy.
Implications of all the available evidence
Autopsy and imaging studies show that vascular amyloid pathology and lobar microbleeds, the hallmarks of CAA, are common fi ndings in otherwise healthy old adults and patients with mild cognitive impairment. Multiple lines of evidence suggest that CAA pathology is an important contributor to subcortical tissue injury through vascular dysfunction and ischaemia. Cerebral amyloid angiopathy is also a well-established contributor to cognitive impairment in elderly patients, independent of intracerebral haemorrhages and other clinical consequences of vascular amyloid deposition. Our study is the fi rst to suggest that CAA pathology might cause cortical atrophy, an eff ect that might at least partly be mediated by vascular dysfunction. These new fi ndings are important to understand the mechanisms of cerebral damage in patients with CAA, because these mechanisms can potentially have disabling clinical eff ects and even confound therapeutic eff orts. For example, some of the immunotherapies studied for Alzheimer's disease (eg, bapineuzumab and gantenerumab) resulted in superfi cial cerebral microbleeds typical of CAA pathology, and accelerated atrophy has been reported in several antibody trials. On the basis of all available evidence, CAA pathology will need to be taken into consideration in future clinical trials for patients with Alzheimer's disease or cognitive impairment.
HCHWA-D; all control individuals underwent genetic testing to rule out HCHWA-D. The diagnosis of HCHWA-D was based on DNA analysis for confi rmation of the codon 693 mutation in the amyloid-β precursor protein gene APP. 17 A total of 26 DNA-proven HCHWA-D mutation carriers and 28 age-matched (to within 5 years) controls were enrolled and demographics, vascular risk factors, and clinical features recorded. 16 The healthy controls from the same communities in Leiden all had genetic testing to rule out HCHWA-D. Individuals with sporadic CAA were enrolled in an ongoing longitudinal cohort study of CAA at Massachusetts General Hospital. Detailed information including demographics, vascular risk factors, and clinical characteristics were recorded at the time of enrolment by AA and SvRf. 9, 11 None of the individuals with CAA had dementia and all were free of symptoms suggestive of new stroke for 6 months before MRI acquisition. All individuals with sporadic CAA had a diagnosis of probable CAA according to the pathologically validated Boston criteria. 18 Patients with sporadic CAA were compared with two groups of age-matched healthy controls with complementary strengths: controls in the Harvard Aging Brain (HAB) study, 19 drawn from the same population as the CAA group but imaged on a diff erent scanner type; and a second control group from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, 20 imaged using the same scanner type and strength as the CAA group. As a positive control group to demonstrate cortical atrophy, we also selected age-matched individuals with Alzheimer's disease from the ADNI database. Age matching was done based on the closest age to the fi rst decimal for age, from the available HAB cohort as well as ADNI healthy control and Alzheimer's disease cohorts. Matching was performed without knowledge of radiological or other individual characteristics. Patient enrolment and data collection for these large studies have been extensively described. 19, 20 Specifi cally, part of the data used in the preparation of this Article were obtained from the ADNI database. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuro psychological assessment can be combined to measure the progression of mild cognitive impairment and early Alzheimer's disease.
Overall, 63 patients without dementia but with probable sporadic CAA were age-matched to 63 healthy controls from the ADNI database, 126 healthy controls from the HAB study, and 63 patients with Alzheimer's disease from ADNI. The institutional review boards of the participating sites have approved this study. All participants completed written informed consent. 11 The blood-oxygen-level-dependent (BOLD) fMRI protocol, using a block design with a visual stimulus, has been previously described. 9 The individuals from the ADNI database underwent similar structural MRI sequences using Siemens 1·5 T scanners at several sites, whereas the healthy controls from the HAB study underwent MRI using a Siemens TrioTim 3 T scanner (12-channel head coil) within the same research facility as the sporadic CAA cohort. 19, 20 Extensive details of MRI acquisition parameters for these studies have been presented in previous publications. 
MRI acquisition
Image processing
Three-dimensional cortical surface reconstruction was done with the FreeSurfer software suite (version 5.3).
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The average cortical thickness of each hemisphere was calculated from representations of the grey-white and pial surfaces by taking into account the spatial and intensity singularities of the examined three-dimensional MPRAGE volume. 24 This pipeline allowed the measurement of cortical thickness to sub-millimetre accuracy in previous validation studies. 24, 25 All the results of the cortical surface reconstruction were visually examined by PF and MEG, and manual interventions done mainly by placing control points at regions distorted by gross pathology. This step improves the quality of segmentation and regional parcellations of the entire brain, when needed. In all patients who had intracerebral haemorrhage, we used results from the unaff ected hemisphere for all cortical and white matter measures, as previously described. [9] [10] [11] Besides cortical thickness, the hippocampal volume and estimated total intracranial volumes were calculated again from FreeSurfer parcellations. 26, 27 The estimated total intracranial volume represents the volume within the cranium and allows correction for head size variation within the population examined. Hippocampal volumes were expressed as a percent of estimated total intracranial volume.
Two other measures of CAA-related structural injury were examined: the total number of lobar microbleeds and the white matter hyperintensity volume. The number of lobar microbleeds was counted on a high resolution susceptibility-weighted MRI, based on previously published guidelines. 28 White matter hyperintensity volume was calculated with a home-made, semiautomated algorithm that produced maps of white matter hyperintensity. 11 All the maps generated by this algorithm were visually checked to verify their accuracy, manually corrected when needed and the white matter hyperintensity volume was expressed as a percentage of estimated total intracranial volume.
The BOLD time-to-peak (in seconds), a physiological marker of vascular reactivity, was calculated from the fMRI acquisitions as described. 
Statistical analysis
The primary objective of the study was to compare cortical thickness between individuals with CAA and healthy controls; the overarching hypothesis was that CAA pathology causes cortical atrophy. Bivariate analyses were done with the χ² test for ratios, and the t test for continuous variables. Bivariate correlation analyses were done to test the association between continuous variables and Spearman's ρ for variables that did not have a normal distribution. Multivariate linear regression models were built to test the association between diagnosis of CAA and cortical thinning, after adjustment for covariates. These covariates were identifi ed based on the results of bivariate analyses in this study and previous reports, and included age, sex, white matter hyperintensity volume, and fi nally hippocampal volume as a surrogate for parenchymal amyloid-related damage. Separate multi variate models were built and reported for each group comparison-ie, sporadic CAA and its comparator cohorts (two control groups and patients with Alzheimer's disease), as well as HCHWA-D and respective controls. Additional multivariable models were done omitting patients with sporadic CAA and intracerebral haemorrhage, to exclude confounding from these lesions. Because lobar microbleeds are part of the presentation and diagnostic criteria for CAA, we used multivariate models restricted to the CAA cohorts to test for their association with cortical thickness. When regression models incorporating all covariates risked overfi tting a model with a relatively 29, 30 For the mediation analysis, the diagnosis (CAA vs healthy control) was used as the independent variable (potential eff ector), time-to-peak of BOLD response as the potential mediator, and cortical thickness as the dependent variable. The Sobel test is useful to estimate the percentage of the total eff ect that is mediated and the results of both approaches were reported. A two-tailed threshold for signifi cance of p<0·05 was used.
A general linear model was computed to schematically explore the regional diff erences in cortical thickness between patients with CAA and healthy controls, after adjusting for age and sex. Topographic surface maps were generated using a threshold of p<0·01 (with false discovery rate correction for multiple comparisons). The resulting maps show the statistically signifi cant regional diff erences in cortical thickness between the CAA and their age-matched healthy control cohorts.
All statistical analyses were done with SPSS software (version 23).
Role of the funding source
The funding source of the study had no role in the performance of this study, analyses, interpretation of results, or manuscript preparation. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. A multivariate linear regression model was built to test the association between diagnosis of HCHWA-D and cortical thinning, after adjustment for covariates that included age, sex, white matter hyperintensity volume, and fi nally hippocampal volume as a surrogate for parenchymal amyloid-related damage. The diagnosis of HCHWA-D was independently associated with lower cortical thickness (p=0·0002). Other variables independently associated with cortical thickness were age and hippocampal volume, but not white matter hyperintensity and sex (data not shown). Cortical thickness did not correlate with white matter hyperintensity or lobar microbleeds in a multivariate model adjusted for age within the HCHWA-D cohort (data not shown).
Results
We tested the generalisability of these fi ndings from a pure CAA cohort to the more common situation of sporadic CAA. We age-matched patients with sporadic CAA (n=63) with individuals from two healthy control cohorts (HAB, n=126; and ADNI, n=63), and patients with Alzheimer's disease (ADNI, n=63; and medial frontal regions (fi gure 2). We repeated these comparisons after excluding 31 patients with CAA who had intracerebral haemorrhage (and their matched healthy controls), to overcome any potential confounding eff ect of these lesions. The remaining 32 patients with CAA without intracerebral haemorrhage again had signifi cantly lower cortical thickness (2·16 mm [SD 0·12]) versus both healthy control groups (both p<0·0001; table 3). The diagnosis of CAA was independently associated with cortical thinning compared with both healthy control groups after adjustment for the covariates above (p=0·007). Similar results were obtained when the multivariate models were limited to CAA patients without intracerebral haemorrhage and corresponding healthy controls (p=0·010). There was again no association between cortical thickness and total number of lobar microbleeds or white matter hyperintensity volume after controlling for age within the sporadic CAA cohort (data not shown).
The patients with Alzheimer's disease were in the early stages of this disease: 36 (57%) had a clinical dementia rating of 0·5 (normal rating 0, abnormal range 0·5-3) and 27 (43%) had a clinical dementia rating of 1. Patients with Alzheimer's disease showed signifi cantly thinner cortices when compared with both the CAA (table 3) and healthy control groups (ADNI healthy vs Alzheimer's disease, mean diff erence -0·20 [95% CI -0·24 to -0·16], p<0·0001; HAB healthy vs Alzheimer's disease -0·16
[-0·20 to -0·13], p<0·0001). Hippocampal volume was signifi cantly reduced in CAA (table 3) versus both healthy control cohorts (both p<0·0001), and was smaller in the Alzheimer's disease than in CAA (mean diff erence -0·05 [95% CI -0·07 to -0·02], p=0·001).
BOLD time-to-peak, a functional marker of vascular reactivity thought to mediate ischaemic injury in CAA, 9, 12 was signifi cantly longer in patients with HCHWA-D than in controls (p<0·0001; table 2). Prolonged BOLD time-topeak correlated with decreased cortical thickness within the HCHWA-D cohort (ρ=-0·58, p=0·003), but not in the age-matched healthy control group (ρ=0·05, p=0·810). Within the HCHWA-D cohort, BOLD time-to-peak remained independently correlated with cortical thickness after adjustment for age, sex, white matter hyperintensity volume, microbleed count, hippocampal volume, and presence of intracerebral haemorrhage (p=0·028). In patients with sporadic CAA, cortical thickness was also negatively correlated with BOLD time-to-peak (r=-0·4, p=0·015) and remained signifi cant after adjusting for the above covariates (p=0·007). We did mediation analyses 29, 30 to address whether some of the eff ect of HCHWA-D on cortical thickness is mediated by vascular dysfunction as measured by prolonged BOLD time-to-peak. There was a signifi cant initial relationship between the diagnosis of HCHWA-D and cortical thickness (β=0·22, p=0·01) that was non-signifi cant after controlling for BOLD time-topeak (β=0·12, p=0·2), indicating that BOLD time-to-peak might mediate the relationship between HCHWA-D diagnosis and cortical thickness. The Sobel test also found BOLD time-to-peak (t=2·4, p=0·018) to be a signifi cant mediator of the infl uence of HCHWA-D on cortical thickness, explaining 63% of the total eff ect.
Discussion
To identify the contribution of cerebrovascular amyloid pathology to cortical atrophy, we evaluated cortical thickness in patients with a monogenic form of CAA largely devoid of parenchymal Alzheimer's disease pathology, as well as in patients with sporadic CAA without dementia. Both hereditary and sporadic CAA groups showed signifi cant decreases in cortical thickness (5-6%) when compared with age-matched healthy controls, whereas patients with Alzheimer's disease exhibited even greater cortical thinning (3%) than agematched patients with sporadic CAA.
Cortical atrophy in CAA could be related to several factors: confounding from concomitant parenchymal Alzheimer's disease pathology; cortical eff ects of CAArelated structural lesions; or CAA-related vascular dysfunction. We addressed the fi rst possibility by minimising the confounding of Alzheimer's disease pathology through the unique opportunity aff orded in patients with HCHWA-D, and noted essentially the same extent and pattern of cortical thinning as in the cohort of sporadic CAA. Our results further showed no major eff ects on cortical thickness of structural lesions, such as Figure 2: Diff erences in cortical thickness between patients with sporadic cerebral amyloid angiopathy and their age-matched controls A general linear model was computed to schematically explore the regional diff erences in cortical thickness between patients with sporadic CAA and healthy controls, after adjusting for age and sex. Topographic surface maps were generated using a threshold of p<0·01 (with false discovery rate correction for multiple comparisons). The resulting maps show the statistically signifi cant regional diff erences in cortical thickness. CAA=cerebral amyloid angiopathy. L=left. R=right.
lobar microbleed or white matter hyperintensity, and suggest instead that vascular dysfunction may at least partly mediate CAA-related cortical damage. A strength of our study was inclusion of patients with HCHWA-D and age-matched controls identifi ed and scanned at a single site. The codon 693 mutation of the amyloid precursor protein gene APP 15 causes extensive amyloid deposition in the walls of meningocortical arterioles, minimal parenchymal Aβ deposition in the form of so-called diff use plaques, and essentially no dense core plaque or tau deposition. 31 We found decreased cortical thickness in this essentially pure phenotype of CAA in relatively young patients (mean age 46 years) and no association between cortical thickness and structural lesions. We have replicated these results in patients with the more prevalent condition of sporadic CAA. Adding hippocampal volume (a commonly used diagnostic biomarker in Alzheimer's disease) as a covariate in multivariate regression models did not change the independent association between CAA and global cortical thinning, further supporting our hypothesis that vascular amyloid directly contributes to cortical atrophy.
Cortical atrophy could be related to any of the various CAA pathology-related lesions: intracerebral haemorrhage, microbleeds, cortical microinfarcts, and even white matter lesions through local or dying-back mechanisms. As in previous studies, 9, 11 we collected data from the hemisphere that was not aff ected by intracerebral haemorrhage, and repetition of all pertinent analyses in the subgroup of patients without intracerebral haemorrhage did not change the results. Lobar microbleed counts and white matter hyperintensity volumes did not correlate with cortical thickness in either CAA cohort in multivariate models, similar to fi ndings reported previously for another small vessel disease, cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy. 32 Future studies designed to detect cortical microinfarcts and measure the remote eff ects of small deep lesions, such as lacunes, will increase our understanding of the mechanisms of cortical atrophy in patients with CAA.
Cortical thinning in CAA was noted in the occipital, temporal, posterior parietal, and medial frontal regions, areas previously reported to be particularly susceptible to vascular amyloid load by pathology and in-vivo amyloid imaging. 6, 33, 34 Amyloid burden in the medial frontal region has also been identifi ed as an independent predictor of future haemorrhages in patients with CAA. 35 Although the distribution of cortical thinning in patients with CAA resembles the distribution of vascular amyloid, it also overlaps with the pattern of cortical thinning observed in Alzheimer's disease, suggesting that these patterns may not be entirely disease specifi c. 36 We did not observe substantial qualitative diff erences in the patterns of cortical thinning between the individuals with hereditary and those with sporadic CAA. Because of substantial age diff erences between the two CAA cohorts (approximately 25 years, with no age overlap) and the large eff ect of age on cortical thickness, we could not quantitatively compare the pattern of cortical thinning between sporadic and hereditary CAA.
BOLD time-to-peak appears to be a marker of vascular dysfunction in patients with sporadic CAA and, on the basis of our data, also in the younger patients with HCHWA-D. 9, 12 There was a strong and independent negative correlation between BOLD time-to-peak and cortical thickness. Consequently, vascular dysfunctionexpressed as delay in haemodynamic response-might contribute to cortical thinning in patients with CAA. Cortical thinning did not correlate with BOLD time-topeak in the respective controls, supporting the conclusion that vascular amyloid, but not the cortical thickness itself, drives this association. Furthermore, both mediation analyses found that vascular dysfunction mediates a signifi cant part of HCHWA-D's eff ect on cortical thinning.
Some recent evidence also suggests reduced blood fl ow and possibly cortical atrophy in patients with CAA: two studies showed grey matter loss and hypometabolism in the temporal lobe of patients with Alzheimer's disease with microbleeds, when compared with Alzheimer's disease without microbleeds, and widespread reductions in cortical perfusion in healthy octogenarians with cortical microbleeds (mean age 87·6 years [SD 2·8]), when compared with age-similar healthy controls without microbleeds (mean age 86·2 years [SD 2·5]). 37, 38 The lack of a dedicated control group for sporadic CAA is a weakness of the study. We note, however, essentially similar diff erences in cortical measures in the two agematched control groups compared with the patients with sporadic CAA, supporting the robustness of the fi ndings. Other notable weaknesses were the lack of fMRI in the fi rst 26 patients with sporadic CAA enrolled early in the study and in the corresponding controls. We cannot exclude the possibility that the parenchymal Aβ that has been observed as diff use plaques in patients with HCHWA-D might have some contribution to cortical thinning even in hereditary CAA. 39 We also again note that, in the absence of a validated molecular tracer specifi c to CAA or Alzheimer's disease pathology, it is impossible to exclude some degree of confounding by concurrent parenchymal Alzheimer's disease pathology on cortical thickness. Eff orts to produce a specifi c marker for CAA are underway. Short of such a specifi c marker, we have analysed a series of neuroimaging markers that capture aspects of CAA severity-lobar microbleeds, white matter hyperintensity volume, vascular reactivity-and fi nd correlation only with vascular reactivity, raising the possibility that this aspect of CAA severity contributes to the CAA-related reduction in cortical thickness. In all other respects, the fi ndings from the sporadic CAA analyses replicated those from the less confounded HCHWA-D analyses, suggesting that the observed cortical thinning and association with vascular dysfunction are indeed driven by advanced CAA pathology.
In conclusion, our fi ndings show that cerebrovascular amyloid pathology is an independent contributor to cortical atrophy and suggest that this eff ect is at least partly mediated by CAA-related vascular dysfunction. These results indicate that a relatively common cerebral small vessel disease results in cortical changes independent of its profound subcortical eff ects. Our results also add support to the view that the contributory role of CAA pathology and small vessel diseases should be considered in eff orts to reduce age-associated cognitive impairment. 
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